Thrombocytopenia is a common manifestation of tumors, which usually caused by myelosuppression bone marrow involvement malignant tumor cells or radiotherapy. Immune thrombocytopenia (ITP), as paraneoplastic syndrome, more in lymphatic proliferative neoplasms and rheumatic diseases, less solid neoplasms, has not been reported peritoneal epithelioid mesothelioma.Herein, we report 45-year-old pati...

The paradigm for managing primary immune thrombocytopenia (ITP) in adults has changed with the advent of rituximab and thrombopoietin receptor agonists (TPO-RAs) as options for second-line therapy. Splenectomy continues to provide the highest cure rate (60%-70% at 5+ years). Nonetheless, splenectomy is invasive, irreversible, associated with postoperative complications, and its outcome is curre...

Thrombopoietin was posited to exist in 1958 and cloned in 1994, and in the ensuing two decades we have learned a great deal about the physiology and pathology of the primary regulator of thrombopoiesis. This paper will review the role of the hormone and its receptor, the product of the c-Mpl proto-oncogene, in health and disease, including many unexpected effects in both normal and neoplastic h...